Syntex participated in a closed meeting of FDA's Arthritis Drugs Advisory Committee May 24-25 to discuss what the committee and FDA would like to seek from companies planning to seek Rx-to-OTC switches for nonsteroidal anti-inflammatory agents, the company told securities analysts July 19. Syntex said that it has not yet submitted an NDA for OTC naproxen, which is being developed under a joint venture with Procter & Gamble. Syntex characterized the meeting as "favorable" and said that the Syntex/P&G joint venture is "on track" to introduce OTC naproxen in the U.S. before the product's patent expires in December 1993.
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.